JAK
Les inhibiteurs de la kinase Janus (JAK) sont des composés qui ciblent la voie de signalisation JAK-STAT, impliquée dans la croissance cellulaire, la réponse immunitaire et l'angiogenèse. En inhibant JAK, ces composés peuvent réduire la signalisation qui conduit à la formation de nouveaux vaisseaux sanguins dans les tumeurs, inhibant ainsi la croissance tumorale. Les inhibiteurs de JAK sont importants dans le traitement des cancers et des maladies inflammatoires. Chez CymitQuimica, nous offrons une gamme diversifiée d'inhibiteurs de JAK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
245 produits trouvés pour "JAK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK-IN-31
CAS :<p>JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,</p>Formule :C21H19N7O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.55JAK-IN-3
CAS :<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Formule :C18H20N4O3Degré de pureté :98.04% - 98.19%Couleur et forme :SolidMasse moléculaire :340.38JAK1-IN-9
CAS :<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formule :C16H13IN6Couleur et forme :SolidMasse moléculaire :416.22JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Couleur et forme :SolidJAK2 JH2 binder-1
CAS :<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62Tyk2-IN-20
CAS :<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Formule :C24H25N7O2Couleur et forme :SolidMasse moléculaire :443.50GDC-9918
CAS :<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Formule :C20H18F2N6O5SCouleur et forme :SolidMasse moléculaire :492.46YLIU-4-105-1
CAS :<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Formule :C32H34F3N7O2Couleur et forme :SolidMasse moléculaire :605.65Cenacitinib
CAS :<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Formule :C19H19F2N7O3Couleur et forme :SolidMasse moléculaire :431.40JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37CP-352664
CAS :<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36TYK2 ligand 2
CAS :<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Formule :C24H20FN7O4Couleur et forme :SolidMasse moléculaire :489.458iBFAR2
CAS :<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Formule :C19H15F3N2O2Couleur et forme :SolidMasse moléculaire :360.33AJI-100
CAS :<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H14FN5OCouleur et forme :SolidMasse moléculaire :323.32Tyk2-IN-3
CAS :<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formule :C25H24N6O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :520.63(3S,4R)-Tofacitinib
CAS :<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37PF-06263276
CAS :<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formule :C31H31FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :566.63(R)-9b
CAS :<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formule :C20H27ClN6OCouleur et forme :SolidMasse moléculaire :402.92JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formule :C20H15ClF3N3OSCouleur et forme :SolidMasse moléculaire :437.87
